{"id":2692,"date":"2026-08-25T13:00:00","date_gmt":"2026-08-25T17:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2692"},"modified":"2026-08-25T19:45:05","modified_gmt":"2026-08-25T23:45:05","slug":"fda-places-regenxbios-rgx-121-on-clinical-hold-after-spine-mri-findings","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2692","title":{"rendered":"FDA Places REGENXBIO’s RGX-121 on Clinical Hold After Spine MRI Findings"},"content":{"rendered":"

Company:<\/strong> REGENXBIO · Asset:<\/strong> RGX-121 (Clemidsogene Lanparvovec) · Indication:<\/strong> Neuronopathic MPS II · Event Type:<\/strong> FDA Clinical Hold · Date:<\/strong> August 24, 2026<\/p>\n

\"20260825_REGENXBIO_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

FDA placed the RGX-121 program on clinical hold after asymptomatic spinal MRI findings were identified in five CAMPSIITE participants treated approximately three to six years earlier. REGENXBIO no longer expects to resubmit the RGX-121 biologics license application in the near term. Investigators classified the findings as nonserious and radiologists considered them likely benign, but their nature, cause and clinical significance are unconfirmed; the regulatory and development consequences are therefore clear while the medical interpretation remains unresolved.<\/p>\n

What Happened<\/h4>\n

The affected participants received intracisternal or intraventricular RGX-121, also called clemidsogene lanparvovec, for neuronopathic mucopolysaccharidosis type II. The company described the spinal findings as a small nodule or small cystic mass; no brain nodules or masses were identified, and the participants were reported to be clinically doing well with stable or improved neurocognitive and neurobehavioral status. Spinal MRI is not routinely performed in MPS II trials or clinical practice, leaving the background prevalence of comparable findings uncertain, and periodic imaging is now planned. The company had not yet disclosed pathological confirmation, a causal mechanism, lesion progression, dose relationship or the complete FDA hold letter. The update reverses near-term regulatory guidance: on August 6, REGENXBIO said FDA had reaffirmed a path to resubmission in the third quarter, but on August 24 the company said it does not expect near-term resubmission. RGX-121 and the related RGX-111 program are partnered with Nippon Shinyaku.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation should separate the verified regulatory signal from the unresolved biology. The hold and deferred resubmission are negative for program timing; they do not establish that RGX-121 caused the lesions, that the lesions are malignant, or that participants are clinically deteriorating. One explanation is a program-specific consequence of CNS administration, disease anatomy or long-term local exposure. A broader explanation is that years-late imaging findings reveal a monitoring gap relevant to other intrathecal or intracisternal AAV programs; different capsids, routes and tissues in REGENXBIO’s other assets argue against automatic platform extrapolation, but they do not eliminate the need for route- and product-specific review. The translational chain now turns on serial imaging, natural-history comparators, lesion characterization, biodistribution, vector integration or pathology if available, dose and route relationships, and FDA requirements.<\/p>\n

Company and Product Background<\/h4>\n

REGENXBIO develops AAV-based gene therapies using its NAV platform. RGX-121 is designed to deliver an iduronate-2-sulfatase gene to the central nervous system, creating a durable source of enzyme for neuronopathic Hunter syndrome, using direct CNS administration to overcome limited blood-brain barrier exposure. MPS II is an X-linked lysosomal storage disorder caused by deficient IDS activity and accumulation of glycosaminoglycans. For CNS gene therapy, the benefit-risk assessment must integrate neurodevelopment, CSF substrate reduction, biodistribution, immunogenicity, dose, local tissue exposure, insertional or proliferative risk, imaging surveillance and long-term durability.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Regulatory Status<\/td>\nFDA clinical hold; near-term BLA resubmission no longer expected<\/td>\n<\/tr>\n
Safety Finding<\/td>\n5 asymptomatic participants with spinal nodule\/cystic-mass findings 3-6 years post-dosing<\/td>\n<\/tr>\n
Clinical Status<\/td>\nNo brain masses; participants reported clinically stable or improved<\/td>\n<\/tr>\n
Platform Read-Through<\/td>\nFindings arose after direct CNS administration; other REGENXBIO programs use different routes<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> The findings are asymptomatic, radiologists consider them likely benign, no brain masses were found, and participants remain clinically stable or improved, all consistent with an incidental finding from unusually intensive imaging surveillance rather than a treatment-related injury.<\/p>\n

Bear case:<\/strong> Clustering of similar findings in five treated participants after direct CNS dosing, combined with FDA’s decision to impose a clinical hold, signals the agency views this as a credible safety concern requiring resolution before the program can proceed.<\/p>\n

InSilens Take<\/h4>\n

The decisive fact is the clinical hold and loss of near-term BLA timing; the decisive uncertainty is medical causation, since neither “likely benign” nor “treatment-related” is yet established. Broader conclusions about REGENXBIO’s other AAV programs or the CNS gene therapy field generally should wait for lesion characterization and regulator-directed analysis rather than being extrapolated from this single program.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Negative · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA placed the RGX-121 program on clinical hold after asymptomatic spinal MRI findings were identified in five CAMPSIITE participants treated approximately three to six years earlier. REGENXBIO no longer expects to resubmit the RGX-121…<\/p>\n","protected":false},"author":1,"featured_media":2699,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[292,431,430],"class_list":["post-2692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-gene-therapy","tag-mucopolysaccharidosis-type-ii","tag-regenxbio"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2692"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2692\/revisions"}],"predecessor-version":[{"id":2704,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2692\/revisions\/2704"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2699"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}